RecruitingPhase 1NCT06808477

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patients

Sponsor

Bambusa Therapeutics

Enrollment

198 participants

Start Date

Feb 27, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BBT001 and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBBT001

BBT001 will be administered

DRUGPlacebo

Placebo will be administered

Locations(7)

Equity Medical, LLC

The Bronx, New York, United States

Linear Clinical Research

Perth, Western Australia, Australia

Optimal Clinical Trials Central Auckland

Grafton, Auckland, New Zealand

Aotearoa Clinical Trials

Otahuhu, Auckland, New Zealand

Pacific Clinical Research Network (PCRN) - Auckland

Takapuna, Auckland, New Zealand

Optimal Clinical Trials Ltd - Christchurch

Christchurch Central City, Christchurch, New Zealand

Pacific Clinical Research Network (PCRN) Wellington

Upper Hutt, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06808477

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0639791116 locations

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT076458204 locations